JP2019520328A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019520328A5 JP2019520328A5 JP2018560588A JP2018560588A JP2019520328A5 JP 2019520328 A5 JP2019520328 A5 JP 2019520328A5 JP 2018560588 A JP2018560588 A JP 2018560588A JP 2018560588 A JP2018560588 A JP 2018560588A JP 2019520328 A5 JP2019520328 A5 JP 2019520328A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- compound
- tissue
- formula
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 18
- 239000008194 pharmaceutical composition Substances 0.000 claims 17
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 6
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 5
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 238000012544 monitoring process Methods 0.000 claims 3
- 238000002600 positron emission tomography Methods 0.000 claims 3
- 230000005855 radiation Effects 0.000 claims 3
- 230000002285 radioactive effect Effects 0.000 claims 3
- 238000003384 imaging method Methods 0.000 claims 2
- 238000012216 screening Methods 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 206010061818 Disease progression Diseases 0.000 claims 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 230000005750 disease progression Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 201000005787 hematologic cancer Diseases 0.000 claims 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 1
- 230000009033 hematopoietic malignancy Effects 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 230000001717 pathogenic effect Effects 0.000 claims 1
- 239000002243 precursor Substances 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662338872P | 2016-05-19 | 2016-05-19 | |
| US62/338,872 | 2016-05-19 | ||
| PCT/US2017/033004 WO2017201111A1 (en) | 2016-05-19 | 2017-05-17 | Pet-imaging immunomodulators |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019520328A JP2019520328A (ja) | 2019-07-18 |
| JP2019520328A5 true JP2019520328A5 (enExample) | 2020-06-25 |
| JP6953444B2 JP6953444B2 (ja) | 2021-10-27 |
Family
ID=59021563
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018560588A Active JP6953444B2 (ja) | 2016-05-19 | 2017-05-17 | Ｐｅｔイメージング用免疫修飾因子 |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US11103605B2 (enExample) |
| EP (2) | EP3827849A1 (enExample) |
| JP (1) | JP6953444B2 (enExample) |
| KR (1) | KR102378288B1 (enExample) |
| CN (1) | CN109414514B (enExample) |
| AU (1) | AU2017268291B2 (enExample) |
| BR (1) | BR112018073642A2 (enExample) |
| CA (1) | CA3024844A1 (enExample) |
| CY (1) | CY1124241T1 (enExample) |
| DK (1) | DK3458111T3 (enExample) |
| EA (1) | EA038019B1 (enExample) |
| ES (1) | ES2864091T3 (enExample) |
| HR (1) | HRP20210644T8 (enExample) |
| HU (1) | HUE054306T2 (enExample) |
| IL (1) | IL262962B (enExample) |
| LT (1) | LT3458111T (enExample) |
| MA (1) | MA53402A (enExample) |
| MX (1) | MX2018014028A (enExample) |
| PL (1) | PL3458111T3 (enExample) |
| PT (1) | PT3458111T (enExample) |
| RS (1) | RS61742B1 (enExample) |
| SG (1) | SG11201810177VA (enExample) |
| SI (1) | SI3458111T1 (enExample) |
| SM (1) | SMT202100238T1 (enExample) |
| WO (1) | WO2017201111A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9856292B2 (en) | 2014-11-14 | 2018-01-02 | Bristol-Myers Squibb Company | Immunomodulators |
| US10143746B2 (en) | 2016-03-04 | 2018-12-04 | Bristol-Myers Squibb Company | Immunomodulators |
| US10358463B2 (en) | 2016-04-05 | 2019-07-23 | Bristol-Myers Squibb Company | Immunomodulators |
| WO2018048882A1 (en) | 2016-09-06 | 2018-03-15 | The Research Foundation For The State University Of New York | Positron imaging tomography imaging agent composition and method for bacterial infection |
| FI3548515T3 (fi) | 2016-12-01 | 2026-03-04 | Regeneron Pharma | Radioleimattuja anti-PD-L1-vasta-aineita immuno-PET-kuvantamiseen |
| IL267572B2 (en) * | 2016-12-23 | 2025-02-01 | Univ Johns Hopkins | Tumor and immune cell imaging based on PD-L1 expression |
| AU2018219909B2 (en) | 2017-02-10 | 2025-02-27 | Regeneron Pharmaceuticals, Inc. | Radiolabeled anti-LAG3 antibodies for immuno-PET imaging |
| EP3642220A1 (en) | 2017-06-23 | 2020-04-29 | Bristol-Myers Squibb Company | Immunomodulators acting as antagonists of pd-1 |
| IL316355A (en) | 2017-07-24 | 2024-12-01 | Regeneron Pharma | Anti-CD8 antibodies and their uses |
| WO2019070643A1 (en) | 2017-10-03 | 2019-04-11 | Bristol-Myers Squibb Company | IMMUNOMODULATORS |
| CN110504017B (zh) * | 2019-07-30 | 2022-06-10 | 哈尔滨医科大学 | 一种示踪剂的制备和使用方法 |
| EP4087857B1 (en) | 2020-01-06 | 2023-11-01 | Bristol-Myers Squibb Company | Immunomodulators |
| JP2023517736A (ja) * | 2020-03-16 | 2023-04-26 | ブリストル－マイヤーズ スクイブ カンパニー | 免疫調節剤 |
| ES2970547T3 (es) | 2020-03-30 | 2024-05-29 | Bristol Myers Squibb Co | Inmunomoduladores |
| US12159403B2 (en) * | 2021-06-18 | 2024-12-03 | The United States Government As Represented By The Department Of Veteran Affairs | Combination of features from biopsies and scans to predict prognosis in SCLC |
| JP2026500238A (ja) * | 2022-12-12 | 2026-01-06 | メルク・シャープ・アンド・ドーム・エルエルシー | グランザイムｂのｐｅｔ造影剤としての環状ペプチド |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5374548A (en) | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
| MX9203291A (es) | 1985-06-26 | 1992-08-01 | Liposome Co Inc | Metodo para acoplamiento de liposomas. |
| US5776093A (en) | 1985-07-05 | 1998-07-07 | Immunomedics, Inc. | Method for imaging and treating organs and tissues |
| US4735210A (en) | 1985-07-05 | 1988-04-05 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
| US5101827A (en) | 1985-07-05 | 1992-04-07 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
| US5128119A (en) | 1989-06-12 | 1992-07-07 | Immunomedics, Inc. | Methods for technetium/rhenium labeling of f(ab1)2 fragments |
| US5328679A (en) | 1988-04-01 | 1994-07-12 | Immunomedics, Inc. | Methods for technetium/rhenium labeling of proteins |
| US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
| US5746996A (en) | 1994-06-03 | 1998-05-05 | Immunomedics, Inc. | Thiolation of peptides for radionuclide-based radiodetection and radiotherapy |
| IL113610A0 (en) | 1994-06-03 | 1995-08-31 | Immunomedics Inc | A method of radiolabeling a protein, radiolabeled proteins prepared thereby and diagnostic kits containing the same |
| US5869451A (en) | 1995-06-07 | 1999-02-09 | Glaxo Group Limited | Peptides and compounds that bind to a receptor |
| US5753206A (en) | 1995-06-07 | 1998-05-19 | Immunomedics, Inc. | Radiometal-binding analogues of luteinizing hormone releasing hormone |
| ATE365562T1 (de) | 1996-05-03 | 2007-07-15 | Immunomedics Inc | Zielgerichtete kombinations-immuntherapie für krebs |
| JP3647881B2 (ja) | 1996-07-12 | 2005-05-18 | イムノメディクス，インコーポレイテッド | 放射性金属元素結合ペプチドの類似化合物 |
| US6277818B1 (en) | 1998-10-29 | 2001-08-21 | Angstrom Pharmaceuticals, Inc. | Cyclic peptide ligands that target urokinase plasminogen activator receptor |
| ATE353864T1 (de) | 1997-09-03 | 2007-03-15 | Immunomedics Inc | Fluorierung von proteinen und peptiden für positronemissionstomographie |
| US9090668B2 (en) | 2007-03-26 | 2015-07-28 | The University Of Tokyo | Process for synthesizing cyclic peptide compound |
| EP2328920A2 (en) | 2008-08-25 | 2011-06-08 | Amplimmune, Inc. | Targeted costimulatory polypeptides and methods of use to treat cancer |
| US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
| JP5818237B2 (ja) | 2010-09-09 | 2015-11-18 | 国立大学法人 東京大学 | Ｎ−メチルアミノ酸およびその他の特殊アミノ酸を含む特殊ペプチド化合物ライブラリーの翻訳構築と活性種探索法 |
| EP2647720B1 (en) | 2010-12-03 | 2019-06-19 | The University of Tokyo | Peptide library production method, peptide library, and screening method |
| WO2013010573A1 (en) * | 2011-07-18 | 2013-01-24 | Universitaet Muenster | Compounds with matrix-metalloproteinase inhibitory activity |
| CN103732238A (zh) | 2011-06-08 | 2014-04-16 | 奥瑞基尼探索技术有限公司 | 用于免疫调节的治疗性化合物 |
| CN104245726A (zh) | 2012-03-29 | 2014-12-24 | 奥瑞基尼探索技术有限公司 | 来自人pd1的bc环的免疫调节环状化合物 |
| JP2013253842A (ja) | 2012-06-06 | 2013-12-19 | Univ Of Tokyo | ｐＨ依存的に標的分子に結合するペプチドのスクリーニング方法 |
| EP2859012B1 (en) | 2012-06-06 | 2017-08-09 | Polyphor AG | Beta-hairpin peptidomimetics |
| US9308236B2 (en) | 2013-03-15 | 2016-04-12 | Bristol-Myers Squibb Company | Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions |
| KR20250091304A (ko) | 2013-03-15 | 2025-06-20 | 제넨테크, 인크. | Pd-1 및 pd-l1 관련 상태를 치료하기 위한 바이오마커 및 방법 |
| AU2014316686B2 (en) | 2013-09-06 | 2018-11-22 | Aurigene Discovery Technologies Limited | Cyclic peptidomimetic compounds as immunomodulators |
| WO2015044900A1 (en) | 2013-09-27 | 2015-04-02 | Aurigene Discovery Technologies Limited | Therapeutic immunomodulating compounds |
| CA2960778C (en) | 2014-09-11 | 2023-03-07 | Bristol-Myers Squibb Company | Macrocyclic inhibitors of the pd-1/pd-l1 and cd80(b7-1)/pd-l1 protein/protein interactions |
| US9732119B2 (en) | 2014-10-10 | 2017-08-15 | Bristol-Myers Squibb Company | Immunomodulators |
| US9856292B2 (en) | 2014-11-14 | 2018-01-02 | Bristol-Myers Squibb Company | Immunomodulators |
| ES2822990T3 (es) * | 2014-11-25 | 2021-05-05 | Bristol Myers Squibb Co | Novedosos polipéptidos de unión a PD-L1 para obtención de imágenes |
| EA034516B1 (ru) | 2014-11-25 | 2020-02-14 | Бристол-Маерс Сквибб Компани | Способы и композиции для мечения радиоактивным изотопомf биологических препаратов |
| US9861680B2 (en) | 2014-12-18 | 2018-01-09 | Bristol-Myers Squibb Company | Immunomodulators |
| US9944678B2 (en) | 2014-12-19 | 2018-04-17 | Bristol-Myers Squibb Company | Immunomodulators |
| US20160222060A1 (en) | 2015-02-04 | 2016-08-04 | Bristol-Myers Squibb Company | Immunomodulators |
| US9809625B2 (en) | 2015-03-18 | 2017-11-07 | Bristol-Myers Squibb Company | Immunomodulators |
| US10143746B2 (en) | 2016-03-04 | 2018-12-04 | Bristol-Myers Squibb Company | Immunomodulators |
| US10358463B2 (en) | 2016-04-05 | 2019-07-23 | Bristol-Myers Squibb Company | Immunomodulators |
| US10994033B2 (en) | 2016-06-01 | 2021-05-04 | Bristol-Myers Squibb Company | Imaging methods using 18F-radiolabeled biologics |
| EP3535280B1 (en) | 2016-11-07 | 2022-03-16 | Bristol-Myers Squibb Company | Immunomodulators |
| EP3642220A1 (en) | 2017-06-23 | 2020-04-29 | Bristol-Myers Squibb Company | Immunomodulators acting as antagonists of pd-1 |
| WO2019070643A1 (en) | 2017-10-03 | 2019-04-11 | Bristol-Myers Squibb Company | IMMUNOMODULATORS |
-
2017
- 2017-05-17 SI SI201730690T patent/SI3458111T1/sl unknown
- 2017-05-17 KR KR1020187036396A patent/KR102378288B1/ko active Active
- 2017-05-17 ES ES17728696T patent/ES2864091T3/es active Active
- 2017-05-17 LT LTEP17728696.0T patent/LT3458111T/lt unknown
- 2017-05-17 US US16/098,765 patent/US11103605B2/en active Active
- 2017-05-17 WO PCT/US2017/033004 patent/WO2017201111A1/en not_active Ceased
- 2017-05-17 CN CN201780042462.1A patent/CN109414514B/zh active Active
- 2017-05-17 PL PL17728696T patent/PL3458111T3/pl unknown
- 2017-05-17 EP EP21152813.8A patent/EP3827849A1/en not_active Withdrawn
- 2017-05-17 HR HRP20210644TT patent/HRP20210644T8/hr unknown
- 2017-05-17 JP JP2018560588A patent/JP6953444B2/ja active Active
- 2017-05-17 EP EP17728696.0A patent/EP3458111B1/en active Active
- 2017-05-17 DK DK17728696.0T patent/DK3458111T3/da active
- 2017-05-17 SM SM20210238T patent/SMT202100238T1/it unknown
- 2017-05-17 EA EA201892635A patent/EA038019B1/ru unknown
- 2017-05-17 MX MX2018014028A patent/MX2018014028A/es unknown
- 2017-05-17 MA MA053402A patent/MA53402A/fr unknown
- 2017-05-17 BR BR112018073642-2A patent/BR112018073642A2/pt unknown
- 2017-05-17 RS RS20210499A patent/RS61742B1/sr unknown
- 2017-05-17 SG SG11201810177VA patent/SG11201810177VA/en unknown
- 2017-05-17 PT PT177286960T patent/PT3458111T/pt unknown
- 2017-05-17 HU HUE17728696A patent/HUE054306T2/hu unknown
- 2017-05-17 CA CA3024844A patent/CA3024844A1/en active Pending
- 2017-05-17 AU AU2017268291A patent/AU2017268291B2/en active Active
-
2018
- 2018-11-12 IL IL262962A patent/IL262962B/en active IP Right Grant
-
2021
- 2021-04-29 CY CY20211100375T patent/CY1124241T1/el unknown
- 2021-08-26 US US17/412,612 patent/US20210386876A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019520328A5 (enExample) | ||
| Brody et al. | Chemokine receptor 2–targeted molecular imaging in pulmonary fibrosis. A clinical trial | |
| Seo et al. | Technological development and advances in single-photon emission computed tomography/computed tomography | |
| Hoh et al. | Positron emission tomography in urological oncology | |
| Schambach et al. | Application of micro-CT in small animal imaging | |
| Tatsumi et al. | Initial experience in small animal tumor imaging with a clinical positron emission tomography/computed tomography scanner using 2-[F-18] fluoro-2-deoxy-D-glucose | |
| JP2019527225A5 (enExample) | ||
| Robin et al. | Diagnostic performance of FDG PET/CT to detect subclinical HNSCC recurrence 6 months after the end of treatment | |
| Estorch et al. | Future challenges of multimodality imaging | |
| Fularz et al. | Utility of PET/CT in the diagnosis of recurrent ovarian cancer depending on CA 125 serum level | |
| Molnar et al. | Impact of PET/CT imaging with FDG in locally advanced cervical carcinoma—a literature review | |
| JP2022016473A (ja) | 肝臓及び／又は腎臓機能の診断剤 | |
| JP2018502829A5 (enExample) | ||
| Yagi et al. | High-throughput multiple-mouse imaging with micro-PET/CT for whole-skeleton assessment | |
| Bélanger et al. | Biodistribution and radiation dosimetry of [11C] DASB in baboons | |
| Suzuki-Shibata et al. | Prognostic value of volumetric FDG PET/CT parameters in patients with oral tongue squamous cell carcinoma who were treated by superselective intra-arterial chemoradiotherapy | |
| US11266755B2 (en) | Development and application of tumor diagnostic radioactive probe targeting folic acid receptor | |
| Hansen et al. | Pulmonary langerhans cell histiocytosis: PET/CT for initial workup and treatment response evaluation | |
| RU2405569C2 (ru) | Способ визуализации "сторожевых" лимфоузлов при раке гортани и гортаноглотки | |
| Yoo et al. | Monitoring of macrophage accumulation in statin-treated atherosclerotic mouse model using sodium iodide symporter imaging system | |
| Schöder et al. | PARP1/2 imaging with 18F-PARPi in patients with head and neck cancer | |
| Boll et al. | Double-contrast micro-CT colonoscopy in live mice | |
| JP2022508692A (ja) | 転移性前立腺がんを処置するための併用療法 | |
| Dunphy et al. | Dosimetry of 18F-labeled tyrosine kinase inhibitor SKI-249380, a dasatinib-tracer for PET imaging | |
| Bradbury et al. | Synchronous Cardiac and Central Nervous System Diffuse Large B-Cell Lymphoma |